Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients

NCT01974258 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Cobimetinib
DRUG: Cobimetinib
DRUG: Onartuzumab
DRUG: Vemurafenib

Sponsor

Hoffmann-La Roche